February 11, 2019 10:21 AM EST
News Briefing

3SBio inks Chi­na deal with Boston-based Verseau; Er­ic Topol calls for dig­i­tal ed­u­ca­tion in NHS re­port

ENDPOINTS

→ Chi­na’s 3SBio has li­censed rights to three im­muno-on­col­o­gy as­sets dis­cov­ered by Verseau Ther­a­peu­tics. Boston-based Verseau has a plat­form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

Te­va launch­es Ste­lara biosim­i­lar at 85% dis­count as wider field emerges

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times